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Background: The Care Programme for the Last Days of Life has been developed to improve the quality of end-of-life
care in acute geriatric hospital wards. The programme is based on existing end-of-life care programmes but modeled
to the acute geriatric care setting. There is a lack of evidence of the effectiveness of end-of-life care programmes and
the effects that may be achieved in patients dying in an acute geriatric hospital setting are unknown. The aim of this
paper is to describe the research protocol of a cluster randomized controlled trial to evaluate the effects of the Care
Programme for the Last Days of Life.
Methods and design: A cluster randomized controlled trial will be conducted. Ten hospitals with one or more acute
geriatric wards will conduct a one-year baseline assessment during which care will be provided as usual. For each
patient dying in the ward, a questionnaire will be filled in by a nurse, a physician and a family carer. At the end of the
baseline assessment hospitals will be randomized to receive intervention (implementation of the Care Programme) or
no intervention. Subsequently, the Care Programme will be implemented in the intervention hospitals over a six-month
period. A one-year post-intervention assessment will be performed immediately after the baseline assessment in the
control hospitals and after the implementation period in the intervention hospitals. Primary outcomes are symptom
frequency and symptom burden of patients in the last 48 hours of life.
Discussion: This will be the first cluster randomized controlled trial to evaluate the effect of the Care Programme for the
Last Days of Life for the acute geriatric hospital setting. The results will enable us to evaluate whether implementation of
the Care Programme has positive effects on end-of-life care during the last days of life in this patient population and
which components of the Care Programme contribute to improving the quality of end-of-life care.
Trial registration: ClinicalTrials.gov Identifier: NCT01890239. Registered June 24th, 2013.
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Pain and symptom management, appropriate treatments
and medication and communication about end-of-life is-
sues are identified as key elements of quality care for
terminally ill patients [1]. However, clinicians are often
inadequately prepared to diagnose dying effectively [2]* Correspondence: rebecca.verhofstede@vub.ac.be
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unless otherwise stated.or to discuss the likelihood of imminent death with pa-
tients and families [3-7]. Studies have also shown that
older hospitalized people are less likely to receive appro-
priate pain control and more likely to receive burden-
some interventions at the end of life than their younger
counterparts [8-11]. Although end-of-life care has been
identified as a priority for older people [8,12] and a large
proportion die in hospital [13-15], the quality of end-of-
life care for older hospitalized patients is suboptimal,
leaving room for improvement [16]. As a significantntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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atric ward of a hospital, it is an important setting in
which end-of-life care could be improved.
To improve the quality of care at the end of life in the
geriatric hospital population we developed and success-
fully piloted the Care Programme for the Last Days of
Life (Verhofstede R, Smets T, Cohen J, Costantini M,
Van Den Noortgate N, van der Heide A, Deliens L:
Development of the care programme for the last days of
life for older patients in acute geriatric hospital wards: a
phase 0–1 study according to the Medical Research
Council Framework, submitted; Verhofstede R, Smets T,
Cohen J, Costantini M, Van Den Noortgate N, Deliens L:
Feasibility and preliminary effects of the Care Programme
for the Last Days of Life in an older acute hospital popula-
tion: mixed-methods study of the success of implementa-
tion and staff perceptions, in preparation). This programme
is based on the Liverpool Care Pathway (LCP) programme,
taking into account the concerns regarding the LCP raised
in the UK and adapted to the geriatric hospital population
and setting (Verhofstede R, Smets T, Cohen J, Costantini
M, Van Den Noortgate N, van der Heide A, Deliens L: De-
velopment of the care programme for the last days of life
for older patients in acute geriatric hospital wards: a phase
0–1 study according to the Medical Research Council
Framework, submitted). The Care Programme essentially
aims to raise awareness among geriatric health care staff of
the importance for improving end-of-life care and to pre-
pare them for a change in end-of-life care, to train staff in
delivering good end-of-life care with the support of a multi-
professional document called the Care Guide for the Last
Days of Life, to support dying geriatric patients with the
Care Guide for the Last days of Life, to regularly evaluate
the delivered end-of-life care and support and to further
educate the staff in delivering optimal end-of-life care. The
Care Programme consists of the following documents:
(1) the Care Guide for the Last Days of Life, (2) supportive
documentation and (3) an implementation guide (Figure 1).
Although end-of-life care programmes have been de-
veloped since the 1990s and have already been imple-
mented in more than 20 countries [17], the available
evidence regarding their effectiveness is weak and stud-
ies are limited to the cancer population. Two systematic
reviews conclude that randomized controlled trials or
other well designed controlled studies are needed to ob-
tain additional evidence about the effectiveness of end-
of-life care pathways [18]. To date, only one cluster
randomized controlled trial has been performed to study
the effects of the LCP in oncology patients dying in Italian
hospitals [19,20]. Results of that study show that a well-
implemented LCP programme has the potential to reduce
the gap in quality of care between hospices and hospitals.
However, the results also show that the effects of the LCP
programme are smaller than those shown in qualitativeand before-and-after non-controlled studies, and no sig-
nificant effects on the overall quality of care were found
[20]. Nonetheless, the effectiveness of the LCP programme
was evaluated in a cancer population whereas end-of-life
care pathways or programmes are often used for patients
who are dying from diseases other than cancer. Further-
more, the study was underpowered and therefore may
have led to underestimated results.
Although it is now widely accepted that clinical practice
should be, wherever possible, evidence-based, clinical
pathways to improve the quality of end-of-life care are
often implemented without a thorough evaluation of their
effectiveness [21]. Additional and robust evidence is re-
quired [18,22] before realizing a large scale implementa-
tion of an end-of-life care pathway. Hence, a thorough
evaluation of the effectiveness of the Care Programme for
the Last Days of Life is needed before implementing it in
practice. We will therefore evaluate the Care Programme
in a phase 3 trial according to the MRC framework [23].
The aim of this article is to describe the research
protocol of the cluster randomized controlled trial that
will be performed to evaluate the effectiveness of a com-
plex intervention, the Care Programme for the Last Days
of Life, in acute geriatric wards.
Methods
Trial design
While a classic randomized clinical trial is known as the
most appropriate method to study the effect of an inter-
vention, it is impossible to randomize a complex inter-
vention within a hospital without contamination of the
control arm [24]. For this reason, a multicentre two arm
cluster randomized controlled trial will be performed.
To prevent possible bias at the level of the hospital, a
clustering will take place on the hospital level. Conse-
quently, randomization will be carried out at the level of
the hospital. The flow diagram of the study protocol is
outlined in Figure 2. The CONSORT guidelines have
been followed to design this study [25]. The trial is regis-
tered in ClinicalTrials.gov, identifier NCT01890239.
Study population
The inclusion criteria of the hospitals in the trial are:
○ the cluster or hospital has one or more acute
geriatric wards
○ the medical and nursing head of one or more acute
geriatric wards per hospital give consent for
participation in the study
The inclusion criteria of patients are:
○ those dying in the acute geriatric ward between
October 2012 and March 2015
Care Programme for the Last Days of Life
Care Guide for the 
Last Days of Life1
Supportive 
documentation
Implementation 
guide2
An information leaflet for 
health care staff about the Care 
Guide for the Last Days of Life
A manual for health care staff 
on how to use Care Guide for 
the Last Days of Life
Three leaflets for family carers 
about the entering of the dying 
phase, grief and bereavement 
and facilities available on the 
acute geriatric ward
Figure 1 The Care programme for the last days of life. 1A multi-professional document that provides a template of care for the last days and
hours of life with recommendations on different aspects of care and guidance for the psychological and spiritual support of patients and their
families. 2This guide assists health care staff in implementing the Care Programme for the Last Days of Life on the geriatric ward during a
six-month period.
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48 hours
○ those having given informed consent at admission for
the use of their personal information from medical or
nursing records for the purposes of the study.General procedures of the cluster RCT
First, a one-year baseline assessment will be conducted
in all participating acute geriatric wards of participating
hospitals. During that period care will be provided as
usual. At the end of the baseline assessment all partici-
pating hospitals with one or more participating wards
will be randomized into intervention or control groups.
In the intervention group the Care Programme for the
Last Days of Life will be implemented over a six-month
period with the support of an implementation guide
(Figure 2). After the implementation period, the inter-
vention group will conduct a one-year post-intervention
assessment during which the Care Guide for the Last
Days of Life will continue to be used. The control group
will continue to provide care as usual and will conduct a
one-year post-intervention assessment directly following
the one-year baseline assessment (Figure 2).Intervention
The Care Programme aims to introduce and embed the
Care Guide for the Last Days of Life, which will be initi-
ated when a patient is diagnosed as dying and which
provides a comprehensive template of evidence-based,
multidisciplinary care for the last days and hours of life.
The Care Programme will be implemented and subse-
quently established according to an implemention guide
incorporating nine components: (1) establishing the im-
plementation project and preparing the environment for
organizational changes, (2) preparing the documenta-
tion, (3) baseline review, (4) training geriatric health care
staff, (5) use of the Care Guide for the Last Days of Life
with intensive support, (6) semi-intensive support,
(7) evaluation, (8) consolidation and (9) ongoing educa-
tion, training and support (Table 1).
The development and content of the Care Programme
for the Last Days of Life are extensively described else-
where (Verhofstede R, Smets T, Cohen J, Costantini M,
Van Den Noortgate N, van der Heide A, Deliens L:
Development of the care programme for the last days of
life for older patients in acute geriatric hospital wards: a
phase 0–1 study according to the Medical Research
Council Framework, submitted).
Hospital (cluster) recruitment
Intervention group
Clusters randomly assigned to 
intervention or control group
Control group
one-year baseline assessment
one-year
post-intervention  assessment
one-year 
post-intervention assessment
six-month implemention of the 
Care Programme for the Last 
Days of Life
usual care
usual care
with implemented 
Care Programme for the 
Last Days of Life
Figure 2 Flowchart of the cluster randomized controlled trial.
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Primary outcome
Quality of dying during the last 48 hours of life: the pa-
tient’s symptom frequency and symptom burden mea-
sured using the EOLD-SM and EOLD-CAD [26].
Secondary outcomes
1. the quality of care during the last three days of life
as perceived by nurses, i.e. physical symptoms,
emotional, psychological and spiritual/existential
needs and provision of information and support
measured using the POS [27]
2. the quality of care during the last 48 hours of life as
perceived by family carers, i.e. satisfaction with the
care provided to the patient during the last 48 hours
of life measured using the EOLD-SWC [26]
3. the content of care during the last 48 hours of life,
i.e. the goal of treatment, medical and nursing
interventions, medication policy
4. the communication among clinical staff, i.e. informing
the family physician about the impending death5. the communication between clinical staff and patients
and/or family carers, i.e. the perception of
communication with the physician during the dying
phase by family carers measured using the FPPFC [28]
6. the level of bereavement of family carers after the
death of the patient measured using the PGD
scale [29].
Process evaluation
We will also evaluate the quality of the process of imple-
mentation in the intervention group. An evaluation tool
was developed to measure the degree to which the Care
Programme for the Last days of Life was implemented
in each ward in compliance with the implementation
guide. For each component of the Care Programme indi-
cators were developed so that the implementation of
each individual component as well as the entire imple-
mentation process could be documented and quantita-
tively evaluated. This evaluation tool has been developed
and piloted in a phase 2 study (Verhofstede R, Smets T,
Cohen J, Costantini M, Van Den Noortgate N, Deliens L:
Feasibility and preliminary effects of the Care Programme
Table 1 Overview of the nine components within the implementation guide
N° Content
Component 1 Establishing the implementation project and preparing the environment
▪ Informing the geriatric health care staff about the implementation project and the importance of change in
care during the last days of life
▪ Executive endorsement: acquiring management approval for the trainings and audits
▪ Involvement of specialist palliative care services is recommended: at least one member of the
Palliative Support Team of the hospital is member of the steering group
▪ Facilitators: a nurse and a physician of the geriatric ward
▪ Formation of steering group: at least four people from the geriatric ward (facilitators included)
▪ Intensive 2-day training of facilitators
Component 2 Preparing the documentation
▪ Development of an information leaflet for family carers about the facilities in the geriatric hospital ward
Component 3 Baseline review
▪ Analyzing end-of-life care data of deceased geriatric hospital patients using the patients’ medical files
Component 4 Training geriatric health care staff
▪ Feedback of the results to the staff and focusing on improvement within the geriatric ward
▪ Facilitators and specialist palliative care colleagues train geriatric health care staff with the aid of a training
package (i.e. hand-outs with information about the Care Guide for the Last Days of Life, a copy of the Care
Guide for the Last Days of Life, a casus to discuss in group etc.)
Component 5 Care Guide use and intensive support
▪ Care Guide use after sufficient training and education
▪ Intensive support and supervision by the steering group through repeated coaching, telephone and
direct guidance, discussion of clinical cases and clinical audits
Component 6 Semi-intensive support
▪ Semi-intensive support and supervision by the steering group through repeated coaching, telephone
and direct guidance, discussion of clinical cases and clinical audits
Component 7 Evaluation
▪ To organize a qualitative evaluation of the implementation: evaluating and discussing the performance
and progress of each of the previous components
▪ The qualitative evaluation acknowledges areas where further support, education or training is needed
Component 8 Consolidation
▪ To adopt a strategy to maintain/improve the implementation and sustainability of the Care Guide
▪ Support and supervision by the steering group through repeated coaching, telephone and direct guidance,
discussion of clinical cases and clinical audits
Component 9 Ongoing education, training and support
▪ Keeping up to date with developments in end-of-life care and a continuing education and evaluation
within the hospital ward
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tion: mixed-methods study of the success of implementa-
tion and staff perceptions, in preparation).
Measurement instruments
Primary and secondary outcomes will be measured
retrospectively after each death on the ward using ques-
tionnaires to be filled out by three different respondent
types: the nurse who was most closely involved in the
care for the deceased patient, the physician who was
most closely involved in the care for the deceased pa-
tient, and a family carer of the deceased patient. Thenurse and family carer questionnaires contain validated
measurement instruments, in addition to self-developed
questions. The physician questionnaire only contains
self-developed questions (Table 2). Regarding the vali-
dated measurement instruments, the nurse question-
naire contains: the End-of-Life in Dementia Scales
Symptom Management (EOLD-SM) [26], the End-of-
Life in Dementia Scales Comfort Assessment in Dying
Management (EOLD-CAD) [26] and the Palliative care
Outcome Scale (POS) [27].
In the questionnaire for the family carer the following
validated instruments are included: the EOLD-SM [26],
Table 2 Content of the three different questionnaires for nurses, physicians and family carers
Questionnaire Questions Scale Primary and secondary outcomes
Nurse Used from a scale EOLD-SM Symptom frequency*
EOLD-CAD Symptom burden*
POS Quality of care
Self-developed questions Content of care, i.e. nursing interventions,
Communication between clinical staff and patients and/or family carers of dying patients
Communication among clinical staff
Physician Self-developed questions Content of care, i.e. goal of treatment, medical interventions, medication policy
Communication among clinical staff
Family carer Used from a scale EOLD-SM Symptom frequency*
EOLD-CAD Symptom burden*
FPPFC Communication between clinical staff and patients and/or family carers of dying patients
EOLD-SWC Quality of care
PGD Level of bereavement
Self-developed questions Communication between clinical staff and patients and/or family carers of dying patients
*primary outcome.
Table 3 Total number of clusters required according to
different average sizes of the clusters and ICC (ES = 0.55,
alpha = 0.05, power = 0.80)
Average size of the clusters
20 30 40
ICC 0.02 10 8 8
0.03 12 10 10
0.04 12 10 10
0.05 14 12 10
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Satisfaction With Care (EOLD-SWC) [26], the Family
Perception of Physician-Family Caregiver Communica-
tion (FPPFC) [28] and the Prolonged Grief Disorder
(PGD) Scale [29]. All three questionnaires have been
cognitively tested in face-to-face interviews with four
nurses, four physicians and three family carers respect-
ively, and were subsequently refined where needed.
Data collection
During the baseline and post-intervention assessment,
questionnaires will be filled in for all patients who died
in the participating geriatric hospital wards and who met
the inclusion criteria. The nurse and physician most
closely involved in the care of the deceased patient will
be asked to fill in a questionnaire within one week of the
death. Six weeks after the death the researcher will send
a questionnaire to a family carer, if they have given in-
formed consent to being contacted by the researcher. In
cases where the family carer does not respond to the
questionnaire up to two reminders will be sent, two
weeks after the initial sending of the questionnaire and
two weeks later.
Sample size calculation
The hypothesis of this cluster randomized trial is
that there will be significant differences in symptom
frequency and symptom burden between patients dying
in the intervention group and those dying in the control
group. Symptom frequency and symptom burden will be
measured using the EOLD-SM and the EOLD-CAD. Be-
cause our primary outcome is a reduction in symptom
frequency and symptom burden during the last 48 hours
of life, we consider a total EOLD-CAD score of 3.2(7.6%) as the minimum clinically important difference
for implementing the Care Programme for the Last Days
of Life [30]. A minimum increase of 3.2 in the interven-
tion group compared to the control group corresponds
with an effect size (EC) of about 0.55. A minimum
change of 5% to 10% has been found to be clinically sig-
nificant for symptom and quality-of-life analyses [31]. In
order to calculate the sample size of this cluster trial two
other elements are essential: the intra-cluster correlation
coefficient and the average size of the cluster (number of
cluster deaths). We estimate an intra-cluster correlation
coefficient of between 0.02 and 0.05 [32] and a conserva-
tive average of 30 deaths per hospital per year based on
observed mortality statistics, taking into consideration
the non-included deceased patients. In Table 3 four ICC
scenarios (from 0.02 to 0.05) intersect with three scenar-
ios of average size of the cluster (from 20 to 40). This
table reports different sample size scenarios necessary to
detect an ES of 0.55 with alpha = 0.05 and a power of
80% conditional on the hypothesized levels of ICC (from
0.02 to 0.05) and average size of cluster (from 20 to 40).
A sample size of six clusters per group with 30 individ-
uals per cluster achieves 80% power to detect a difference
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relation is 0.05 using a Two-Sided T-test with a signifi-
cance level of 0.05.
Recruitment of hospitals
Based on the cluster size calculation, 10 to 12 hospitals
with one or more acute geriatric wards must be re-
cruited. In order to recruit these hospitals, the study has
been presented at three geriatric meetings. Shortly after
these meetings information letters were sent to geriatri-
cians. Geriatricians who were interested in participating
were contacted by the researcher to make an appoint-
ment to explain and discuss the study and to sign an
agreement of participation form. If geriatricians did not
spontaneously contact the researcher, the researcher
took the initiative herself to contact the geriatricians by
phone about their interest and possible participation.
Randomization
At the end of the baseline assessment the included hos-
pitals with one or more participating acute geriatric
wards will be randomly assigned to the intervention
group (implementing the Care Programme for the Last
Days of Life) or to the control group (usual care).
As the number of clusters to be randomized is consider-
ably smaller than in trials where the unit of randomization
is the patient, there is a chance of baseline imbalance be-
tween the randomized groups. The risk of baseline differ-
ences can be reduced using pair-matched randomization
[33]. Hospitals will be matched in comparable pairs in
terms of 1) the number of deaths per year for the partici-
pating geriatric wards, and 2) the motivation of the partici-
pating wards in terms of the number of patients from
whom they will acquire informed consent for participation
in the baseline measurement period. Information related
to the number of deaths and motivation per hospital will
be sent to a statistician outside the research group, who
will then match the pairs and randomize the hospitals into
the experimental and control group using a random num-
ber generator.
Statistical analysis
All data collected through the three different question-
naires will be stored and collected in Ghent University
Hospital using IBM SPSS Statistics. Data cleaning will be
performed via SPSS syntax operations. All statistical tests
will be done two-tailed with 95% confidence intervals. A
p-value <0.05 will be considered statistically significant.
Descriptive statistics
Cluster and patient characteristics will be reported as mean
and standard deviation (SD) or frequency and percentage
respectively for continuous and categorical variables. The
distribution of characteristics of clusters allocated asexperimental or control hospitals will be compared with
the Student t-test (for continuous variables), with non-
parametric tests (for ordinal variables) and with the
Pearson Chi-square (for binary or nominal variables).
Multivariable analysis
Our primary aim is to detect any differences in the
EOLD-SM [26] and EOLD-CAD [26] between those
dying in the intervention wards and those dying in the
control wards. The primary statistical analysis will be by
intention-to-treat, using multi-level models, taking into
account clustering by hospitals. Because these primary
outcomes are continuous, hierarchical linear models
will be used which will be adjusted for the average level
of quality of life and quality of care provided to the
baseline assessment. This method of analysis will also
be used for our secondary outcome measures. For the
assessment of categorical secondary outcomes, the hier-
archical logistical model will be used.
Informed consent procedure
In order to guarantee privacy for patients whose data is
collected in the study, certain procedures are necessary.
As the Central Ethics Committee requires that data can
only be collected from deceased patients who have given
informed consent prior to the study, written informed
consent to use personal data for the study will be re-
quested by a nurse from each patient at the time of ad-
mission of the patient to the ward. If the patient is
lacking in capacity, written informed consent will be re-
quested from a family carer. Questionnaires will be filled
in only for patients with informed consent at admission.
The physician and the nurse who were closely involved
in the care of a deceased patient will be asked to fill in a
questionnaire about the patient. If one of them refuses
to complete the questionnaire the nurse who is respon-
sible for the study on the ward will pass the question-
naire to another nurse or physician. A closely involved
family carer will also be asked to fill in a questionnaire
about their deceased relative and about their own expe-
riences of care in the dying phase. In order for the re-
searcher to be allowed to send a questionnaire to the
family carer, a nurse will ask informed consent of the
family carer shortly after the death of the patient. Family
carers who give informed consent will be asked to sign a
written informed consent form including their contact
details. If the nurse in the hospital is unable to ask in-
formed consent from the family carer shortly after the
death of the patient, the hospital will send an informed
consent form by post to the family carer two weeks after
the death of the patient asking permission for the re-
searcher to contact them. Family carers who give in-
formed consent to being contacted by the researcher
will be sent a questionnaire six weeks after the patient’s
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consent to fill in the questionnaire.
Ethical approval
The study is approved by the Central Ethics Committee
of the Vrije Universiteit Brussel (VUB) (Belgium) and by
the Local Ethics Committees of the participating hospi-
tals in Flanders.
Discussion
This will be the first cluster randomized controlled trial
to evaluate the effectiveness of the Care Programme for
the Last Days of Life for the acute geriatric hospital set-
ting. Following a baseline assessment, geriatric hospital
wards will be randomized to the intervention or control
group where the Care Programme will be implemented
or care will be provided as usual. A post-intervention as-
sessment should allow us to detect differences in the symp-
tom frequency and symptom burden between patients in
the intervention wards and those in the control wards.
A cluster RCT design has several important strengths.
The first advantage of this robust design is that a control
group will be used. Working with control hospitals can
avoid the situation where differences between the base-
line and post- intervention assessments within the inter-
vention group are caused by changes other than the
intervention that is being studied. Secondly, in all par-
ticipating hospital wards the quality of care and the
quality of life during the last 48 hours of life will be
assessed before and after implementation of the care
programme. That means that we will be able to compare
end-of-life care in geriatric hospital wards before and
after the implementation of our intervention, and that
each hospital operates as its own control. A third
strength of this design is that cluster randomized trials,
unlike individually randomized controlled trials, can re-
duce the effect of treatment contamination as one or
more geriatric wards from one hospital will handle the
same care principles [34]. Fourth, this design may also
increase compliance due to group participation.
This study also has several limitations. Firstly, the
study questionnaires address symptoms and care during
the last 48 hours of life, which is more or less the target
period of the Care Guide. However, it is unknown how
long the geriatric patients will be supported by the Care
Guide for the Last Days of Life. Earlier studies have
shown that the median duration and average time of use
of the LCP in the hospital setting was 16 and 29 hours
respectively [35,36]. However, another study found that
44% of hospice patients were supported by the LCP dur-
ing two days [37]. We therefore cannot preclude that we
may be measuring the quality of care during a period
when the Care Guide had not yet been put into effect,
which could dilute the apparent effect of the CareProgramme. A second limitation, inherent to the focus on
the last 48 hours of life, is that evaluations of a patient’s
quality of life, content of care and communication will de-
pend on after-death evaluations by proxies (nurses, physi-
cians and family carers). However, in selecting the items
for the questionnaires, we have taken into account the re-
liability and validity of proxy-reporting. Proxy measure-
ments have, for instances, been shown to be relatively
valid for relatively objective information such as the pro-
cesses of care [38]. In former retrospective studies, be-
reaved family carers and professional caregivers, like
nurses and physicians, have acted as proxy respondents
and the reliability of proxy assessments for various aspects
of end-of-life care and quality of life are well described
[39]. The aspects we choose to measure are those that
have shown sufficient agreement between patients and
proxy respondents: observable physical symptoms, evalu-
ation of care, service use and awareness of diagnosis [40].
We will also investigate some aspects that are more sub-
jective such as psychological symptoms. It is known that
in comparison with patients, nurses and family carers tend
to overestimate the severity of such symptoms whereas
physicians tend to underestimate them [39]. We therefore
take into account the different perspectives of nurses, phy-
sicians and family carers.
Most end-of-life care pathways or programmes such
as the LCP have been studied in different healthcare set-
tings and have focused mainly on oncology patients.
However, due to the ageing population and a simultan-
eous increase in the incidence of chronic diseases, future
research evaluating the effects of end-of-life care path-
ways or programmes should also focus on elderly people
dying of causes other than cancer [12,8]. Evaluating the
Care Programme for the Last Days of Life for the acute
geriatric hospital patient would therefore add evidence
of the effectiveness of initiatives aimed at improving the
quality of life and care for older patients dying in acute
geriatric hospital wards.
By using a cluster randomized controlled trial design,
the proposed study will contribute substantially to the
increase in evidence for end-of-life care interventions.
To our knowledge only one other cluster RCT in this area
has studied the effects of the LCP programme on cancer
patients dying in Italian hospitals [19,20]. A cluster RCT is
a challenging, high-risk research design. However, results
from a before-after cluster phase 2 trial support the need
for multi-centre cluster randomized controlled trials [41],
as this is the only feasible method of assessing the effect-
iveness of end-of-life care interventions [19].
Conclusions
This will be the first cluster randomized controlled
trial aimed at evaluating the effectiveness of the Care
Programme for the Last Days of Life to improve the
Verhofstede et al. BMC Geriatrics  (2015) 15:13 Page 9 of 10quality of care and quality of life during the last 48 hours
of life of patients dying in acute geriatric hospital wards.
Using this robust study design will allow us to describe
in detail the quality of care and quality of life of elderly
people dying in hospitals and will add to the evidence
about the effectiveness of the Care Programme in the
acute geriatric hospital setting. The poor quality of end-
of-life care in hospitals remains a concern and dealing
with that problem is a public health priority. We hope
that this study will not only show whether the Care
Programme for the Last Days of Life is effective in geriatric
hospital wards but will also provide an understanding of
the contribution of the different components of the Care
Programme to end-of life care.
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